KOREA WHO
-
-
Chairman of Celltrion Group
Seo Jung-jin
Returned to Management After 3 Years, Aims to Challenge Big Pharma as a New Drug Developer
-
Last Updated on Jan 17, 2025
-
Chairman of Celltrion Group
Copy Url : https://www.koreawho.com/profile/SeoJungjin- Life Summary
Seo Jung-jin is the chairman of Celltrion Group.
He is transforming Celltrion from a biosimilar (biopharmaceutical generic drug) company into a new drug developer.
He was born on October 23, 1957, in Cheongju, Chungcheongbuk-do.
He graduated from Jemulpo High School in Incheon and majored in Industrial Engineering at Konkuk University, where he also earned a master's degree from the Graduate School of Industry.
He began his career at Samsung Electro-Mechanics.
He later moved to the Korea Productivity Center, where he was responsible for consulting Daewoo Motors, eventually being selected as an advisor for planning and finance at Daewoo Motors.
In 1999, he founded "Nexol," the predecessor of Celltrion.
Although he stepped down from management as Celltrion Group shifted to a professional management system, he returned to lead the company.
He aims to make the company a global pharmaceutical leader with KRW 10 trillion (US$ 7.2 billion) in revenue by 2030.
When things do not go smoothly, he tackles problems hands-on to find solutions. He enjoys work to the extent that he considers business trips abroad a hobby.
#SeoJungJin #CelltrionGroup #biosimilar #newdrugdevelopment #pharmaceutical #DaewooMotors #SamsungElectroMechanics #globalpharma #KoreanCEO #businessstrategy
He is transforming Celltrion from a biosimilar (biopharmaceutical generic drug) company into a new drug developer.
He was born on October 23, 1957, in Cheongju, Chungcheongbuk-do.
He graduated from Jemulpo High School in Incheon and majored in Industrial Engineering at Konkuk University, where he also earned a master's degree from the Graduate School of Industry.
He began his career at Samsung Electro-Mechanics.
He later moved to the Korea Productivity Center, where he was responsible for consulting Daewoo Motors, eventually being selected as an advisor for planning and finance at Daewoo Motors.
In 1999, he founded "Nexol," the predecessor of Celltrion.
Although he stepped down from management as Celltrion Group shifted to a professional management system, he returned to lead the company.
He aims to make the company a global pharmaceutical leader with KRW 10 trillion (US$ 7.2 billion) in revenue by 2030.
When things do not go smoothly, he tackles problems hands-on to find solutions. He enjoys work to the extent that he considers business trips abroad a hobby.
#SeoJungJin #CelltrionGroup #biosimilar #newdrugdevelopment #pharmaceutical #DaewooMotors #SamsungElectroMechanics #globalpharma #KoreanCEO #businessstrategy
- Related News
- - Seo Jung-jin to Take Celltrion Holdings to NASDAQ, Boosts Celltrion Pharm's Value to Create 'Unified Celltrion'
- - Celltrion’s Seo Jung-jin Pushes U.S. Sales, Set to Harvest First New Drug Zympentra Next Year
- - Celltrion's Value-Up Index Momentum Falters: What Will Become of Seo Jung-jin's Push for a Unified Corporation
- - Seo Jung-jin Confident in KRW 5 Trillion Revenue Next Year with Zymfentra, Considers CDMO Expansion
- - Seo Jung-jin's U.S. Efforts Pay Off, Celltrion Targets KRW 3.5 Trillion Revenue in First Year Post-Merger
- - Shareholders Divided on Celltrion-Celltrion Pharm Merger, Seo Jung-jin Faces Tough Persuasion
- Life Summary
- Career Highlights & Challenges
- · New Drug Candidate Development Strategy Unveiled, Advancing as a New Drug Developer
- · To Enhance Shareholder Value, Repurchasing Treasury Shares
- · Subsidiary Launched for Contract Development and Manufacturing (CDMO) Business
- · First Year of Unified Celltrion, Revenue Exceeds KRW 3 Trillion
- · Autoimmune Disease Treatment Zymfentra Gains Early Foothold in U.S. Market
- · Merger Between Celltrion and Celltrion Pharm Falls Through
- · Celltrion Holdings IPO to Establish KRW 100 Trillion Fund
- · Seo Jung-jin Returns as Chairman of Celltrion’s Three Boards
- · Pioneering Healthcare Business Through Telemedicine
- · First Domestic Company to Develop a COVID-19 Treatment
- · Vision 2030: KRW 40 Trillion Investment in Pharma-Bio Industry
- · Launching 'Celltrion Entertainment' to Enter the Entertainment Industry
- · Transition to Professional Management in 2021
- · First Bio Venture Designated as a Quasi-Conglomerate
- · Celltrion Skincure's Struggles in Cosmetics Business
- · Establishment of Celltrion
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- - Celltrion Fined for Alleged Unfair Support to Seo Jung-jin's Private Companies
- - Received KRW 52.2 Billion in State Funding but Controversy Over 'Outstanding' Research Rating Despite COVID-19 Treatment Failure
- - Controversy Over Out-of-Wedlock Children, Biological Mother Filed by Seo Jung-jin with Police
- - Celltrion Healthcare Accounting Fraud Allegations
- - Celltrion Loses Gift Tax Refund Lawsuit Related to 'Unfair Internal Transactions'
- - Seo Jung-jin Fined for Violating Fair Trade Act
- - Allegations of Power Abuse on a Korean Air Flight
- - Celltrion Holdings Fined for Violating Holding Company Requirements
- - Withdrawal of Stock Sale Plan and Stock Manipulation Allegations
- Professional Timeline
- Educational Background
- Family & Personal Connections
- Awards & Recognitions
- Additional Information
- Notable Quotations
- Infographic & Photos